Myriad Genetics Phase 3 Trial in Alzheimer's Disease is Proceeding on Schedule

SALT LAKE CITY, Aug. 2 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), announced today that enrollment in its Phase 3 trial of Flurizan™ in patients with mild stages of Alzheimer's disease is proceeding on schedule. The Company's amended protocol was reviewed by the FDA without any changes or request for modification and the central Investigational Review Board covering a majority of the investigational sites has given its approval of the modified protocol. More than 120 sites across the United States have been enlisted and most are now screening and enrolling patients into the study. Myriad anticipates completing enrollment for the 12-month study during the first half of 2006 and reporting the results of the Phase 3 trial in the third calendar quarter of 2007.

Myriad used the results of its Phase 2 trial of Flurizan™, which were presented at the Alzheimer's Association International Conference on Prevention of Dementia in June, to fine tune its Phase 3 trial. The Phase 2 study indicated that patients with mild Alzheimer's disease treated with 800 mg Flurizan™ twice daily, experienced the greatest benefit, with a 34% slowing in the rate of cognitive decline. This finding also guided Myriad to size the study to show statistical significance given a 30% improvement versus placebo with 90% confidence.

"We believe that the Phase 3 trial of Flurizan™ in Alzheimer's disease is well-powered to convincingly demonstrate the impressive therapeutic effect that was seen in mild Alzheimer's disease in the Phase 2 trial," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "By concentrating on the mild population, using the higher 800 mg dose, and maintaining consistency among most of the other study variables, we believe we have paved the way for a successful trial."

Myriad is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include: continued enrollment in the Company's Phase 3 trial of Flurizan™ in patients with mild stages of Alzheimer's disease proceeding on schedule; subsequent reviews or comments by the FDA or central Investigational Review Board regarding the protocol for the Phase 3 trial; the number of sites screening and enrolling patients in the study; anticipating completing enrollment for the 12-month study during the first half of 2006; reporting results of the Phase 3 trial in the third calendar quarter of 2007; the powering of the Phase 3 trial to convincingly demonstrate therapeutic effect; and the anticipated success of the Phase 3 trial. These forward-looking statements are based on management's current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, uncertainties as to the extent of future government regulation of Myriad Genetics' business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine business and products. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2004. All information in this press release is as of August 2, 2005, and Myriad undertakes no duty to update this information unless required by law.